Axsome Therapeutics Inc. shares dipped over 2% on Tuesday — their worst session in nearly two weeks — after the company ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

Reports Q4 revenue $118.8M, consensus $117.84M. “2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly ...

Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1 per share. The biopharmaceutical company posted revenue of ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...